Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides perspective on the IPATential150 study in metastatic castration-resistant prostate cancer (mCRPC) presented at the 2020 ESMO Virtual Congress ESMO20

Tags: ESMOProstate

Published: 15 October 2020

Recent Videos: Prostate

video

Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

Dr. Efstathiou, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of ...

video

Arun Azad, MBBS, PhD, FRACP, on the evolving treatment landscape of advanced prostate cancer

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, speculates on how recent clinical trials focused on ...

video

Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020

Dr. Galsky, Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director, Center of ...

video

Arun Azad, MBBS, PhD, FRACP, considers how recent clinical trials influence the treatment of mCRPC

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, considers how treatment algorithms for metastatic castration-resistant prostate ...

video

Arun Azad, MBBS, PhD, FRACP, tells us about the outcomes of the PROfound study presented at ESMO '20

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, tells us about the outcomes of the PROfound ...

video

Arun Azad, MBBS, PhD, FRACP, shares impressions of the post-hoc analysis of the ARCHES study

Dr. Azad, Associate Professor, Medical Oncologist, Peter MacCallum Cancer Centre, Victoria, Australia, shares impressions of the post-hoc analysis of the ...

video

Nicholas James, MD, PhD, offers a summary of the STAMPEDE study to date

Dr. James, Professor of Clinical Oncology, The Institute of Cancer Research, London, tells us about the results of the STAMPEDE ...

Related Videos

video-image

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

video-image

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

video-image

Matthew Galsky, MD, on how studies focused on genetic mutations impact prostate cancer treatment

video-image

Arun Azad, MBBS, PhD, FRACP, on the evolving treatment landscape of advanced prostate cancer

video-image

Matthew Galsky, MD, discusses the practice-changing potential of the PROfound study from ESMO 2020

video-image

Arun Azad, MBBS, PhD, FRACP, considers how recent clinical trials influence the treatment of mCRPC

video-image

Arun Azad, MBBS, PhD, FRACP, tells us about the outcomes of the PROfound study presented at ESMO '20

video-image

Arun Azad, MBBS, PhD, FRACP, shares impressions of the post-hoc analysis of the ARCHES study

video-image

Nicholas James, MD, PhD, offers a summary of the STAMPEDE study to date

video-image

Nicholas James, MD, PhD, analyzes the duration of response in Arm G of the STAMPEDE clinical trial

video-image

Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020

video-image

Maha Hussain, MD, provides perspective on the Phase III PROfound study presented at ESMO 2020

video-image

Maha Hussain, MD, shares the design of the Phase III PROfound study in mCRPC

video-image

Maha Hussain, MD, considers the role of homologous recombination repair in the management of mCRPC

video-image

Maha Hussain, MD, regarding the evolving treatment landscape of mCRPC

video-image

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

video-image

Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer

video-image

Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix

video-image

Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection

video-image

Derek Raghavan, MD, provides a general overview of prostate cancer therapies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imaging

video-image

Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in advanced prostate cancer

video-image

Nicholas Vogelzang, MD, provides thoughts on the role of radium 223 in management of advanced metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in metastatic prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, considers the dosing effects of cabazitaxel in clinical studies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on CARD study impressions comparing novel hormonal therapy to cabazitaxel

video-image

Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticals

video-image

Tomasz Beer, MD, FACP, discusses the recently FDA approved relugolix

video-image

Tomasz Beer, MD, FACP, provides preliminary data presented concerning androgen receptor degraders

video-image

Tomasz Beer, MD, FACP, on how to treat patients who are progressing on androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, explains which nmCRPC patients to treat with androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC

video-image

Scott Tagawa, MD, elaborates on what may account for resistance to PSMA radioligand therapies

video-image

Scott Tagawa, MD, explains how PSMA PET imaging is utilized with PSMA-based therapies

video-image

Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter PMSA-linked therapies

video-image

Scott Tagawa, MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC

video-image

Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC

video-image

Fred Saad MD, on SPARTAN study highlights for oncologists that do not specialize in prostate cancer

video-image

Fred Saad, MD, on genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Fred Saad, MD, shares impressions of the CARD study investigating cabazitaxel in nmCRPC patients

video-image

Fred Saad, MD, details safety concerns when prescribing apalutamide + ADT to nmCRPC patients

video-image

Fred Saad, MD, shares the design and outcomes of the SPARTAN study in patients with nmCRPC

video-image

Scott Tagawa, MD, on promising PSMA products in development for prostate cancer treatment

video-image

Scott Tagawa, MD, shares results of phase 1 dose escalation study of 225Ac-J591 in metastatic prostate cancer patients

video-image

Bradley McGregor, MD, on metastatic renal cell cancer patients whose cancer returns and were previously treated with I-O

video-image

Tanya Dorff, MD, on the future of cellular immunotherapy versus checkpoint inhibition in mPC

video-image

Tanya Dorff, MD, shares thoughts of the optimal sequence of atezolizumab and sip-T in mCRPC

video-image

Oliver Sartor, MD, on the exciting recent outcomes investigating Lu-177–PSMA in patients with advanced prostate cancer

video-image

Lucia Nappi, MD, explains micro RNA usage to aid in the diagnosis and treatment of testicular cancer

video-image

Anis Hamid, describes how RNA profiling guides treatment decisions about chemotherapy for metastatic prostate cancer

video-image

Anis Hamid, MD, describes real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Daniel P. Petrylak, MD, explains the effect of second antigen spread in metastatic castration resistant prostate cancer patients

video-image

Daniel P. Petrylak, MD, shares potential efficacy when adding immunotherapy such as sip-T in metastatic castration resistant prostate cancer

video-image

Landon Brown, MD, shares real world evidence regarding immunotherapy, RCC, and brain metastasis

video-image

Bradley McGregor, MD, shares presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, regarding recent outcomes investigating 225Ac-PSMA-617 in patients with advanced prostate cancer

video-image

Landon Brown, MD, defines CTC chromosomal instability and neuroendocrine phenotype

video-image

Rana McKay, MD, elaborates on presented data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Andrew Armstrong, MD, provides insight as to genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Andrew Armstrong, MD, shares updates on the ARCHES study investigating enzalutamide in metastatic prostate cancer patients

video-image

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markers

video-image

Tom Beer, MD, explains whether PFS2 is a legitimate endpoint in prostate cancer clinical trials

video-image

Tom Beer, MD, shares impressions of the TITAN study invesigating 1st line therapy in mCRPC patients

video-image

Jeanny Aragon-Ching, MD, summarize the EV103 study investigating enfortumab + pembrolizumab

video-image

Jeanny Aragon-Ching, MD, explains efficacy and toxicities differences as they are used in NM-CRPC

video-image

Jeanny Aragon-Ching, MD, discusses STOMP trial data regarding surveillance vs directed therapy

video-image

Daniel P. Petrylak, MD, on the integration of liquid biopsy being targeted into the treatment of prostate cancer

video-image

Daniel P. Petrylak, MD, on the current role of circulating tumor cell components via liquid biopsy prostate cancer treatment

video-image

Oliver Sartor, MD, on future use of liquid biopsy into the treatment of prostate cancer

video-image

Tanya Dorff, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Oliver Sartor, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Anis Hamid, MD, on impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Rana McKay, MD, shares impressions of the CARD study investigating the role of cabazitaxel in mCRPC

video-image

Andrew Armstrong, MD, shares impressions of the CARD study investigating cabazitaxel in metastatic castration-resistant prostate cancer patients

video-image

Tom Beer, MD, shares impressions of the CARD study investigating cabazitaxel in mCRPC patients

video-image

Jeanny Aragon-Ching, on the impact of the genomic classifier testing when choosing patients with mPC

video-image

Rana McKay, MD, on the real world impact of immunotherapy when added to oral therapies for advanced prostate cancer

video-image

Andrew Armstrong, MD, explains whether ARV-7 is predictive of response to taxanes in metastatic prostate cancer patients

video-image

Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Oliver Sartor, MD, shares data of cellular immunotherapy within the African American population

video-image

Anis Hamid, MD, describes quality of life analysis' impact treatment of metastatic prostate cancer

video-image

Landon Brown, MD, on abiraterone or enzalutamider treatment relating chromosomal instability

video-image

Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer

video-image

Jeanny Aragon-Ching, MD, on next generation imaging and its impact on prostate cancer treatment

video-image

Daniel P. Petrylak, MD shares his thoughts on the CARD prostate cancer study presented at ASCO GU 2020

video-image

Tom Beer, MD on the data presented at ASCO GU20 investigating atezolizumab and cabozantinib in metastatic castration resistant prostate cancer

video-image

Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

video-image

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

video-image

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

video-image

Tomasz M. Beer MD, FACP, considers the role of metformin in castrate-resistant prostate cancer

video-image

Tomasz M. Beer MD, FACP, on the efficacy of abiraterone + enzalutamide in mCRPC

video-image

Tomasz M. Beer MD, FACP, discusses outcomes from the TITAN study in mCSPC

video-image

Nancy A. Dawson, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tomasz M. Beer MD, FACP, tells us about the ENZAMET study in mHSPC

video-image

Nancy A. Dawson, MD, regarding the ENZAMET study in mHSPC presented at ASCO '19

video-image

William Oh, MD, tells us about the results of Keynote-365 in mCRPC

video-image

William Oh, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

William Oh, MD, considers the role of biomarker selection trials in prostate cancer

video-image

William Oh, MD, discusses outcomes from the TITAN study in mCSPC

video-image

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

video-image

Kim Chi, MD, speculates on upcoming prostate cancer PARP inhibitor trials

video-image

Kim Chi, MD, provides perspective on biomarker selection trials in prostate cancer

video-image

Kim Chi, MD, regarding the TITAN study presented at ASCO 2019

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on identifying the best patients for Zytiga versus Xtandi

video-image

Nancy Dawson, MD, on how hormone-sensitive advanced prostate cancer should be treated

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer

video-image

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer ASCO GU 2016

video-image

Using new therapies earlier in prostate cancer may returns better results

video-image

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

video-image

Eleni Efstathiou, MD, PhD, shares thoughts on the TROPHY-U-01 clinical study presented at ESMO 2020

video-image

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

video-image

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

video-image

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

video-image

Ken Kato, MD, PhD, on the role of PD-L1 biomarkers in the treatment of esophageal cancer

video-image

Matthew Galsky, MD, considers the implications of the IMvigor130 clinical study

video-image

Matthew Galsky, MD, on the CheckMate-274 study in high risk, muscle-invasive urothelial carcinoma

video-image

Ken Kato, MD, PhD, regarding the treatment of adenocarcinoma versus squamous cell carcinoma

video-image

Matthew Galsky, MD, regarding the TROPHY-U-01 study presented at the 2020 ESMO Virtual Congress

video-image

Ken Kato, MD, PhD, shares the design and outcomes of the Keynote-590 trial from ESMO 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study

video-image

Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials

video-image

Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020

video-image

Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020

video-image

Ana Maria Arance Fernandez, MD, PhD, on the combination of TKIs and checkpoint inhibitors

video-image

Ana Maria Arance Fernandez, MD, PhD, regrading the LEAP-004 clinical trial presented at ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, regarding the antibody-drug conjugate tisotumab vedotin

video-image

Ana Maria Arance Fernandez, MD, PhD, on the progress & data in melanoma coming out of ESMO 2020

video-image

Geoffrey Y. Ku, MD, elaborates on the promising PRS-343 compound

video-image

Robert L. Coleman, MD, FACOG, FACS, shares results of the innovaTV 204 study in cervical cancer

video-image

Roy S. Herbst, MD, PhD, shares thoughts on the update to Keynote-024 presented at ESMO 2020

video-image

David S. Hong, MD, regarding the Phase I clinical trial investigating sotorasib (AMG 510)

video-image

Geoffrey Y. Ku, MD, discusses results of the Phase I study investigating PRS-343 in GI malignancies

video-image

Jaffer Ajani, MD, elaborates on the role of PD-L1 biomarkers in determining treatment decisions

video-image

Robert L. Coleman, MD, FACOG, FACS, on next steps in the clinical development of tisotumab vedotin

video-image

Roy S. Herbst, MD, PhD, elaborates on the design and outcomes of the EMPOWER-lung 1 clinical study

video-image

David S. Hong, MD, speculates on the next steps in the development of sotorasib (AMG 510)

video-image

Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, shares his impressions of the SOLO-1 update from ESMO 2020

video-image

Roy S. Herbst, MD, PhD, tell us about the PIONeeR study presented at the 2020 ESMO Virtual Congress

video-image

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

video-image

Robert L. Coleman, MD, FACOG, FACS, on the role of HRD in the management of ovarian cancer

video-image

Roy S. Herbst, MD, PhD, offers his impressions of the ADAURA trial presented at ESMO 2020

video-image

Geoffrey Y. Ku, MD, on treating squamous cell carcinoma versus adenocarcinoma of the esophagus

video-image

Robert L. Coleman, MD, FACOG, FACS, tells us about the negative outcomes from the IMagyn050 study

video-image

Alex Spira, MD, PhD, FACP, on the practice-changing potential of the ADAURA study from ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, offers thoughts on the four-year follow-up to the Phase III PACIFIC trial

video-image

Alex Spira, MD, PhD, FACP, shares thoughts on the Phase I CHRYSALIS study presented at ESMO 2020

video-image

Alex Spira, MD, PhD, FACP, discusses the mechanism of action of amivantamab (JNJ-6372)

video-image

Petros Grivas, MD, PhD, offers perspective on the JAVELIN Bladder 100 trial updated at ESMO 2020

video-image

Alexander Stratigos, MD, PhD, speculates on next steps in the development of cemiplimab in BCC

video-image

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

video-image

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, regarding the potential challenges when combining checkpoint inhibitors

video-image

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

video-image

Petros Grivas, MD, PhD, discusses the COVID-19 and Cancer Consortium (CCC19) from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, on the latest data investigating the use of cemiplimab in BCC

video-image

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

video-image

Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing

video-image

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

video-image

Petros Grivas, MD, PhD, on whether the results of TROPHY-U-01 justify a larger Phase III study

video-image

Zarnie Lwin, MBBS, FRACP, speculates on future development of combo pembrolizumab + lenvatinib

video-image

Alexander Stratigos, MD, PhD, considers the effectiveness of hedgehog inhibitors in BCC

video-image

Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers

video-image

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCC

video-image

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan

video-image

Petros Grivas, MD, PhD, offers thoughts on the TROPHY-U-01 clinical study from ESMO 2020

video-image

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, provides perspective on the PD-1 biomarker in BCC

video-image

Zarnie Lwin, MBBS, FRACP, on the safety and efficacy of combining TKIs with checkpoint inhibitors

video-image

Andrew Schmidt, MD, speculates on next steps for the COVID-19 and Cancer Outcomes study (CCOS)

video-image

Cristina Suárez, MD, on what physicians should consider when combining checkpoint inhibitors & TKIs

video-image

Andrew Schmidt, MD, regarding the predicted surge in the number of cancer patients due to COVID-19

video-image

Cristina Suárez, MD, on patient subtype responses to combo nivolumab + cabozantinib in 1st line RCC

video-image

Cristina Suárez, MD, offers opinion on whether the CheckMate 9ER trial is practice-changing

video-image

Andrew Schmidt, MD, on interventions that may help correct the disparity in cancer care disruptions

video-image

Cristina Suárez, MD, compares the control arm of CheckMate 9ER with current 1st line RCC regimens

video-image

Andrew Schmidt, MD, on the nature of COVID-19 cancer care disruptions among minority populations

video-image

Cristina Suárez, MD, elaborates on the outcomes of the CheckMate 9ER study presented at ESMO 2020

video-image

Andrew Schmidt, MD, regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented at ESMO 2020

video-image

Cristina Suárez, MD, on the promise of I-O in advanced renal cell carcinoma

video-image

Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients

video-image

Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials

video-image

Giuseppe Giaccone, PhD, MD, speculates on next steps in the development of Tedopi (OSE2101)

video-image

Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib

video-image

Giuseppe Giaccone, PhD, MD, regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCLC

video-image

Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020

video-image

Pasi A. Jänne, MD, PhD, offers opinion on the next steps in the development of mobocertinib

video-image

Giuseppe Giaccone, PhD, MD, regarding the mechanism of action of Tedopi (OSE2101)

video-image

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer

video-image

Pasi A. Jänne, MD, PhD, shares data from ESMO 2020 investigating mobocertinib

video-image

Giuseppe Giaccone, PhD, MD, comments on the incidence of HLA-A2 positive (NSCLC)

video-image

Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer

video-image

Pasi Jänne, MD, PhD, elaborates on EGFR exon 20 insertions in non-small cell lung cancer

video-image

Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

video-image

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

video-image

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

video-image

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

video-image

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

video-image

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

video-image

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

video-image

Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC

video-image

Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC

video-image

Shirish M. Gadgeel MBBS, speculates on the future of RET-altered NSCLC

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

Robert L. Coleman, MD, FACOG, FACS, on the VELIA, PAOLA-1 and PRIMA studies

video-image

Amer Zeidan, MBBS, on his study investigating onvansertib + cytarabine or decitabine in AML

video-image

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

video-image

Brian Van Tine, MD, shares some of the top studies in sarcoma presented at ESMO 2019

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC

video-image

Nader Sanai, MD, shares details from the most promising studies in glioma presented at ESMO 2019

video-image

Christian Rolfo, MD, PhD, MBA, on the development of RET-Fusion in NSCLC

video-image

Ulrik Lassen, MD, PhD, discusses the incidence of TRK fusion in various tumor types

video-image

Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer

video-image

Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab

video-image

Shirish M. Gadgeel MBBS, regarding the most exciting data in lung cancer from ESMO 2019

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

Brian Van Tine, MD, considers the role of real-world outcomes in the treatment of sarcoma

video-image

Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma

video-image

Jason J. Luke, MD, FACP, on the role of CAR-Ts in the treatment of solid tumors

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

David Gershenson, MD, tells us what's new in the treatment of rare epithelial cancers

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Arndt Vogel, MD, shares his impression of the FIGHT-202 trial in cholangiocarcinoma

video-image

Ahmed Kaseb, MD, considers the effectiveness of bevacizumab + atezolizumab in HCC

video-image

Brian Van Tine, MD, discusses the design of the SPEARHEAD-1 trial

video-image

Jason J. Luke, MD, FACP, on the most compelling data in metastatic melanoma from ESMO 2019

video-image

Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC

video-image

Christopher J. Hoimes, MD, considers the role of I-O in perioperative muscle-invasive bladder cancer

video-image

Brian Van Tine, MD, on the most promising investigational agents in advanced sarcoma

video-image

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanoma

video-image

Ahmed Kaseb, MD, offers opinion on nivolumab + ipilimumab in resectable HCC

video-image

Christopher J. Hoimes, MD, comments on the design and outcomes of KEYNOTE-866

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Christopher J. Hoimes, MD, regarding the EV-103 study presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Suresh Ramalingam, MD, provides perspective on the PD-L1 and TMB biomarkers in lung cancer

video-image

David Spigel, MD, on how results from the FLAURA study impact treatment selection in lung cancer

video-image

Suresh Ramalingam, MD, offers opinion on optimal sequencing of immunotherapy in NSCLC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

David Spigel, MD, tells us about the results of CheckMate-227 presented at ESMO 2019

video-image

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

video-image

Marwan Fakih, MD, considers implications from the AMG 510 trial

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

David Spigel, MD, on the use of genomic markers like TMB to guide 1st NSCLC treatment

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors

video-image

Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer

video-image

Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients

video-image

Suresh Ramalingam, MD, discusses the results of CheckMate 227 in advanced NSCLC patients

video-image

Nader Sanai, MD, on the role of ribociclib in the management of gliomas

video-image

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

video-image

Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC